These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 17301806)
1. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Szczepański T Leukemia; 2007 Apr; 21(4):622-6. PubMed ID: 17301806 [TBL] [Abstract][Full Text] [Related]
2. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Brüggemann M; Gökbuget N; Kneba M Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491 [TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in acute leukemia. van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219 [TBL] [Abstract][Full Text] [Related]
4. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608 [TBL] [Abstract][Full Text] [Related]
5. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Gaipa G; Basso G; Biondi A; Campana D Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107 [TBL] [Abstract][Full Text] [Related]
6. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857 [TBL] [Abstract][Full Text] [Related]
7. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774 [TBL] [Abstract][Full Text] [Related]
8. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. van der Velden VH; Wijkhuijs JM; Jacobs DC; van Wering ER; van Dongen JJ Leukemia; 2002 Jul; 16(7):1372-80. PubMed ID: 12094263 [TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970 [TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681 [TBL] [Abstract][Full Text] [Related]